7 completed, 1 withdrawn. 6 Phase 1, 3 Phase 2.
By phase and status
Follow BI 836880: new trials by email Literature Review of BI 836880 trials Research Report on BI 836880
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer BI 765063, Ezabenlimab, BI 836880 - Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 1 Completed 48 2022-04-12 2026-09-16 A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer BI 754091, BI 836880 - Anal Canal Squamous Cell Carcinoma Phase 2 Withdrawn 2020-09-14 2021-11-15 A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) BI 836880 - Wet Macular Degeneration Phase 1 / Phase 2 Completed 43 2019-06-27 2024-11-20 A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer BI 836880, BI 754091 - Neoplasms Phase 1 Completed 21 2019-06-12 2025-10-06 Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors Phase 2 Completed 211 2019-03-19 2026-01-27 A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours BI 836880, Ezabenlimab - Non-squamous, Non-Small-Cell Lung Cancer, Neoplasms Phase 1 Completed 252 2018-07-05 2025-11-10 Weekly BI 836880 in Patients With Advanced Solid Tumors BI 836880 - Neoplasms Phase 1 Completed 24 2016-04-04 2025-10-01 Dose Finding Study of BI 836880 in Patients With Solid Tumors BI 836880 - Neoplasms Phase 1 Completed 29 2016-01-05 2025-10-01
Conditions studied Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1) · Squamous Cell Carcinoma of Head and Neck (1) · Wet Macular Degeneration (1)
Sponsors Boehringer Ingelheim (8)
Countries France (4) · United Kingdom (4) · United States (4) · Germany (3) · Spain (3) · Japan (2) · Poland (2) · South Korea (2) · Australia (1) · Canada (1) · Hong Kong (1) · Malaysia (1) · Mexico (1) · Moldova (1) · Romania (1)
Results publications PMID 36108560 , PMID 39402675 , PMID 37140602
NIH funding 2017 (2) , 2014 (1) , 2015 (1) , 2018 (1) , 2019 (1)